Novel compound may boost function of patients with MCI

07/16/2013 | (free registration)

A study presented at an Alzheimer's disease conference found that CHF5074, an experimental gamma-secretase modulator, may improve the executive and verbal memory functions of patients with mild cognitive impairment. CHF5074 also appears to have potential in partially restoring the immune response of the brain. "We think that this medication may be a start, the first step -- perhaps a baby step -- in preventing the memory loss that of course is the classic hallmark that Dr. Alzheimer described in the early 1900s," researcher Dr. Joel Ross said.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations